| The Banff 97 working classification of renal allograft pathology LC Racusen, K Solez, RB Colvin, SM Bonsib, MC Castro, T Cavallo, ... Kidney international 55 (2), 713-723, 1999 | 3810 | 1999 |
| Banff 07 classification of renal allograft pathology: updates and future directions K Solez, RB Colvin, LC Racusen, M Haas, B Sis, M Mengel, PF Halloran, ... American journal of transplantation 8 (4), 753-760, 2008 | 2331 | 2008 |
| Reduced exposure to calcineurin inhibitors in renal transplantation H Ekberg, H Tedesco-Silva, A Demirbas, © Vítko, B Nashan, A Gürkan, ... New England Journal of Medicine 357 (25), 2562-2575, 2007 | 2253 | 2007 |
| Immunosuppressive drugs for kidney transplantation PF Halloran New England Journal of Medicine 351 (26), 2715-2729, 2004 | 2078 | 2004 |
| International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology KIM Solez, RA Axelsen, H Benediktsson, JF Burdick, AH Cohen, ... Kidney international 44 (2), 411-422, 1993 | 1780 | 1993 |
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence J Sellarés, DG De Freitas, M Mengel, J Reeve, G Einecke, B Sis, ... American Journal of Transplantation 12 (2), 388-399, 2012 | 1755 | 2012 |
| Banff’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (’CAN’) K Solez, RB Colvin, LC Racusen, B Sis, PF Halloran, PE Birk, ... American Journal of Transplantation 7 (3), 518-526, 2007 | 1410 | 2007 |
| Antibody‐mediated rejection criteria–an addition to the Banff′ 97 classification of renal allograft rejection LC Racusen, RB Colvin, K Solez, MJ Mihatsch, PF Halloran, ... American Journal of Transplantation 3 (6), 708-714, 2003 | 1373 | 2003 |
| The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative … M Haas, A Loupy, C Lefaucheur, C Roufosse, D Glotz, D Seron, ... American Journal of Transplantation 18 (2), 293-307, 2018 | 1075 | 2018 |
| Interleukin-2–receptor blockade with daclizumab to prevent acute rejection in renal transplantation F Vincenti, R Kirkman, S Light, G Bumgardner, M Pescovitz, P Halloran, ... New England Journal of Medicine 338 (3), 161-165, 1998 | 1075 | 1998 |
| Costimulation blockade with belatacept in renal transplantation F Vincenti, C Larsen, A Durrbach, T Wekerle, B Nashan, G Blancho, ... New England Journal of Medicine 353 (8), 770-781, 2005 | 1031 | 2005 |
| A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group Transplantation 61, 1029-1037, 1996 | 989 | 1996 |
| Banff’09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups B Sis, M Mengel, M Haas, RB Colvin, PF Halloran, LC Racusen, K Solez, ... American journal of transplantation 10 (3), 464-471, 2010 | 946 | 2010 |
| Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure G Einecke, B Sis, J Reeve, M Mengel, PM Campbell, LG Hidalgo, ... American Journal of Transplantation 9 (11), 2520-2531, 2009 | 805 | 2009 |
| MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS: A Pooled Efficacy Analysis of Three Randomized, Double-Blind, Clinical Studies in Prevention of Rejection: 1 P Halloran, T Mathew, S Tomlanovich, C Groth, L Hooftman, C Barker Transplantation 63 (1), 39-47, 1997 | 711 | 1997 |
| Rethinking chronic allograft nephropathy: the concept of accelerated senescence PF Halloran, A Melk, C Barth Journal of the American Society of Nephrology 10 (1), 167-181, 1999 | 599 | 1999 |
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure RS Gaston, JM Cecka, BL Kasiske, AM Fieberg, R Leduc, FC Cosio, ... Transplantation 90 (1), 68-74, 2010 | 596 | 2010 |
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining B Sis, GS Jhangri, S Bunnag, K Allanach, B Kaplan, PF Halloran American Journal of Transplantation 9 (10), 2312-2323, 2009 | 552 | 2009 |
| Banff 2011 Meeting report: new concepts in antibody-mediated rejection M Mengel, B Sis, M Haas, RB Colvin, PF Halloran, LC Racusen, K Solez, ... American Journal of Transplantation 12 (3), 563-570, 2012 | 517 | 2012 |
| THE SIGNIFICANCE OF THE ANTI–CLASS I RESPONSE PF Halloran, J Schlaut, K Solez, NS Srinivasa Transplantation 53 (3), 550-555, 1992 | 444 | 1992 |
